Dyne Therapeutics Inc. Common Stock (DYN)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses with consistent earnings and a margin of safety. Dyne fails most of Graham's basic tests. It reported no revenue in fiscal Q2 2026, the quarter ended 2026-06-30, fiscal Q1 2026, the quarter ended 2026-03-31, or FY2025, the year ended 2025-12-31. Losses are large and growing: net loss was $178.6M in the quarter ended 2026-06-30, $120.9M in the quarter ended 2026-03-31, $446.2M in FY2025, $317.4M in FY2024, and $235.9M in FY2023. Trailing free cash flow was -$499.2M, a FairStock FCF yield of -17.5%. FairStock's ROE is -81.57% and ROCE is -38.96%. Its Piotroski F-Score is 0/9, and FairStock Score is 30/100. The Lynch category is none because losses occurred in each of the last four years. On the positive side, D/E is 0.33 and Altman Z-Score is 4.52, suggesting some balance-sheet cushion under those models. But P/B is 3.61 for a company with negative returns, and P/E is -4.69, which is meaningless without profits. At the 2026-10-13 close of $15.30, market cap is $2.9B and the 52-week range is $14.00-$27.31. The potential moat is the FORCE platform and neuromuscular pipeline, but it is unproven. Until there is revenue, profits, and positive cash flow, valuation depends on future clinical success. I cannot underwrite this on current numbers; it is a speculative science bet, not a proven business.

In plain English: Dyne Therapeutics is a clinical-stage biotech trying to develop treatments for neuromuscular diseases such as myotonic dystrophy, Duchenne muscular dystrophy, and Pompe disease. It has no product revenue yet and has been losing large amounts of money, including $178.6 million in the quarter ended June 30, 2026, and $446.2 million in the year ended December 31, 2025. At $15.30, the stock is near the low end of its 52-week range, but without profits or sales, the price mostly reflects hopes for its drug pipeline rather than current business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer